
Eton Pharmaceuticals (NASDAQ:ETON) raised its 2026 revenue outlook after reporting record first-quarter product sales and highlighting early progress from two recent product launches, DESMODA and HEMANGEOL.
Chief Executive Officer Sean Brynjelsen said the company now expects full-year revenue to exceed $120 million, up from prior guidance of $110 million. He attributed the higher outlook to first-quarter outperformance, continued portfolio momentum midway through the second quarter, and greater confidence in the HEMANGEOL launch.